IP Library › Granted Patent US 12,391,677
Granted Patent B2
US 12,391,677 · App. 17/284,149 · Granted Aug 19, 2025

Thyroid hormone receptor agonists

Inventors: Xing Dai (Shanghai, CN); Yaolin Wang (Shanghai, CN); Yueheng Jiang (Shanghai, CN); Yanqin Liu (Shanghai, CN); Zixing Han (Shanghai, CN); Zhenwu Wang (Shanghai, CN); Liangshan Tao (Shanghai, CN); Zhe Shi (Shanghai, CN)
Assignee: INVENTISBIO CO., LTD.
C07D403/12A61K31/501A61K31/53A61P5/16C07D401/14C07D403/10C07D403/14C07D405/14C07D413/14C07D471/04C07F9/650905
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,391,677
App. No.
17/284,149
Granted
Aug 19, 2025
Kind
B2
Abstract

Provided herein are novel thyroid hormone receptor (TR) agonists e.g., having Formula I, II, or III. Also provided are methods of preparing the novel TR agonists and method of using the novel TR agonists for treating diseases or disorder modulated by TR agonists, such as NAFLD, NASH, diabetes, hyperlipidemia and/or hypercholesterolemia.

Claims (10)

1. A compound selected from Compound Nos. 27, 35, and 66, or a pharmaceutically acceptable salt thereof:

2. A pharmaceutical composition comprising the compound of claim 1 or a pharmaceutically acceptable salt thereof, and optionally a pharmaceutically acceptable carrier.

3. A method of treating a disease or disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein the disease or disorder is hyperlipidemia, hypercholesterolemia, diabetes, non-alcoholic steatohepatitis, non-alcoholic fatty liver disease, or a combination thereof.

4. A method of treating a liver disease or disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein the liver disease or disorder is non-alcoholic steatohepatitis or non-alcoholic fatty liver disease.

5. The method of claim 4 , wherein the liver disease or disorder is non-alcoholic steatohepatitis.

6. The method of claim 4 , wherein the liver disease or disorder is non-alcoholic fatty liver disease.

7. A method of treating a lipid disease or disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the compound of claim 1 or a pharmaceutical salt thereof, wherein the lipid disease or disorder is hyperlipidemia and/or hypercholesterolemia.

8. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein the compound is

9. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein the compound is

10. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein the compound is

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 9, 2021
From: DAI, XING; WANG, YAOLIN; JIANG, YUEHENG; LIU, YANQIN; HAN, ZIXING; WANG, ZHENWU; TAO, LIANGSHAN; SHI, ZHE
To: INVENTISBIO CO., LTD.
Reel/Frame 055877/0539 →
Priority Claims (2)
WO PCT/CN2018/109942 · Oct 12, 2018 · international
WO PCT/CN2019/075501 · Feb 20, 2019 · international
Continuity (1)
Related Publication 20210355110A1 · Nov 18, 2021
References Cited (12)
US 11964964B2 · Jin et al. · 2024 [cited by applicant]
CN 111801324 · 2020 [cited by applicant]
EP 1471049 · 2004 [cited by applicant]
WO 2007009913 · 2007 [cited by applicant]
WO WO2007009913A1 · 2007 [cited by examiner]
WO 2009037172 · 2009 [cited by applicant]
WO 2014043706 · 2014 [cited by applicant]
Fletcher et. al. ((2017, Comprehensive Cognitive Assessments are not Necessary for the Identification and Treatment of Learning Disabilities, Archives of Clinical Neuropsychology, 32, 2-7 (Year: 2017). [cited by examiner]
Muller et. al. ((2015), New Treatment options for hearing loss, Nature Reviews Drug Discovery, 14, 346-365 (Year: 2015). [cited by examiner]
Martha J. Kelly et al., “Discovery of 2-[3,5-Dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yloxy)phenyl]-3,5-dioxo-2,3,4,5-tetrahydro[1,2,4]triazine-6-carbonitrile (MGL-3196), a Highly Selective Thyroid Hormone R… [cited by applicant]
International Search Report for PCT/CN2019/110494 mailed Jan. 16, 2020, 6 pages. [cited by applicant]
Written Opinion of the ISA for PCT/CN2019/110494 mailed Jan. 16, 2020, 6 pages. [cited by applicant]